Loading...

BMY BRISTOL MYERS SQUIBB CO Investments/Divestments 8-K Filing

BRST

BMY

BRISTOL MYERS SQUIBB CO

(BMY)

2023 8-K

Show Summary

Show Summary

Financial Statements

Management Change

Earnings Announcement

Q3 Earnings Report

Earnings Report

Appointment of Director

Amendment Approval

Earnings Release

Departure of Directors

Acquisition of Karuna Thera...

Offering of Notes

Management Changes

Mini-Tender Offer Rejected

Financial Results Announcement

Investor Presentation

Merger Agreement

Offering of Notes

Management Changes

Earnings Release

Share Repurchase Program

Earnings Release

Appointment of Christopher ...

Earnings Release

Management Changes

Acquisition and Contingent ...

Earnings Release

Departure of Dr. Rupert Vessey

Investor Presentation

External Links:

Bristol-Myers Squibb completed a public offering of $1 billion aggregate principal amount of 5.750% Notes due 2031, $1 billion aggregate principal amount of 5.900% Notes due 2033, $1.25 billion aggregate principal amount of 6.250% Notes due 2053, and

AI Assistant

BRISTOL MYERS SQUIBB CO

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.